Otonomy Shares Fall After OTIVIDEX Trial Fails To Meet Primary Endpoint

Shares of biopharmaceutical company Otonomy Inc (NASDAQ: OTIC) are falling premarket on Monday after the company revealed its Phase 3 trial of OTIVIDEX in patients with Ménière’s disease did not achieve the primary endpoint.

“We are disappointed by the top-line results for the primary intent-to-treat population and are undertaking an assessment to understand the difference observed with the per-protocol analysis,” said David A. Weber, president and CEO of Otonomy.

“Our focus turns to the strong pipeline we have built as recently highlighted by the successful clinical trial results for OTO-313 in tinnitus and OTO-413 in hearing loss,” added Weber.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

The trial’s primary endpoint was the count of definitive vertigo days in Month 3 for OTIVIDEX vs placebo for the intent-to-treat population using the Negative Binomial Model.

Otonomy’s share price has fallen over 49% following the news, currently trading at $2.73 per share.